Track topics on Twitter Track topics that are important to you
Alzheimer’s disease is the most common form of dementia, the collective term for a range of degenerative neurological conditions that affect memory, thinking, behaviour and emotion. There is no cure for dementia and has been no new treatment for the symptoms of dementia since 2002.
Dr Roger M. Perlmutter, President of Merck Research Laboratories, said, “We are disappointed with this outcome, especially given the lack of treatment options for patients suffering from Alzheimer’s disease . . . despite this outcome, Merck remains committed to developing novel therapies for the treatment of Alzheimer’s and other neurodegenerative diseases.”
Paola Barbarino, CEO of Alzheimer’s Disease International, welcomed the continued dedication of Merck, known as MSD in Europe, to identify new and potential treatments for dementia.
More investment is needed to support research on dementia. The World Alzheimer Report 2016 outlines key recommendations for improving health systems for dementia globally.
Original Article: Merck remain committed after discontinuing Verubecestat studyNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...